Clinical Report: Telehealth-Enabled Subcutaneous Ketamine Treatment at Home

Overview

This study evaluates the safety, feasibility, and clinical outcomes of telehealth-enabled subcutaneous ketamine treatment for adults with moderate to severe depression, anxiety, or PTSD.

Background

Major depressive disorder (MDD), generalized anxiety disorder, and posttraumatic stress disorder (PTSD) are significant contributors to global disability. Despite advancements in treatment, access to effective care remains limited, exacerbated by the COVID-19 pandemic which highlighted the need for innovative delivery methods such as telehealth.

Data Highlights

No numerical data provided in the source material.

Key Findings

• Telehealth-enabled subcutaneous ketamine treatment was evaluated for safety and feasibility.
• The study included a diverse cohort of adults with moderate to severe depression, anxiety, or PTSD.
• Access to mental health care remains a critical issue, with only 28% of the U.S. population having adequate access to professionals.
• Telemedicine has gained acceptance as a viable alternative to in-person care during the COVID-19 pandemic.

Clinical Implications

Further research is needed to establish safety and efficacy in this delivery model.

Conclusion

Further studies are necessary to validate these findings.

Related Resources & Content

1. Chen S, et al., EClinicalMedicine, 2025 -- Dynamic changes and future trend predictions of the global burden of anxiety disorders
2. Liu Q, et al., J Psychiatr Res, 2020 -- Changes in the global burden of depression from 1990 to 2017
3. Alonso J, et al., Depress Anxiety, 2018 -- Treatment gap for anxiety disorders is global
4. Thornicroft G, et al., Br J Psychiatry, 2017 -- Undertreatment of people with major depressive disorder
5. FDA's Compounding Risk Alerts
6. HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026
7. VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder
8. These highlights do not include all the information needed to use SPRAVATO safely and effectively. See full prescribing information for SPRAVATO. SPRAVATO® (esketamine) nasal spray, CIII Initial U.S. Approval: 1970 (ketamine)
9. Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial - PMC
10. Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis | American Journal of Psychiatry
11. Effectiveness and safety of repeat dose subcutaneous ketamine for treatment-resistant depression, and the impact of prior ketamine treatment: open label extension of the KADS study | The British Journal of Psychiatry | Cambridge Core
12. VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder